Update on Tutivia™ test adoption

Verici Dx plc

("Verici Dx" or the "Company")

Update on Tutivia™ test adoption

9 new transplant centres on-boarded

19% increase in ordering clinicians in Q3

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces positive progress in its plans to drive strong Tutivia™ sales growth following the equity fundraise completed in July.

Commercial scale-up of Tutivia test adoption, a test for acute rejection post transplant, has progressed in Q3, with a 19% increase in ordering clinicians in the quarter, and the addition of nine new centres, making a total of 30 transplant centres now onboarded, representing 16% of annual transplants in the US. Volume growth from this progress is expected from Q4 and the number of orders in Q3 were consistent with the previous two quarters.

The Company has expanded its commercial team with three new senior sales hires. In addition, a Director of Clinical Partnerships will be joining the commercial team in mid-October.

The Board continues to target meeting market expectations for the full year.

Investor presentation

Sara Barrington, Chief Executive Officer, and David Anderson, Chief Financial Officer, will provide a live presentation via the Investor Meet Company platform on 7 October at 10.00 am BST. This presentation is open to all existing and potential shareholders. Questions can be submitted at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet VERICI DX PLC via:

https://www.investormeetcompany.com/verici-dx-plc/register-investor

Investors who already follow Verici Dx on the Investor Meet Company platform will automatically be invited.